关节突关节与骶髂关节疼痛皮质类固醇注射多学会共识建议
由美国区域麻醉与疼痛医学学会等多家学会发起,采用改良德尔菲法与USPSTF分级,形成关节突关节和骶髂关节皮质类固醇注射安全性与有效性共识。共识涵盖注射技术安全性、皮质类固醇对疗效的影响及相关不良事件,并给出常用剂量建议。
要点
- 关节突关节内注射皮质类固醇对有炎症者可缓解疼痛并改善功能。
- 骶髂关节关节内、关节外及联合给药均有效。
- 每个关节突关节10 mg甲基泼尼松龙或曲安奈德、每个骶髂关节40 mg为合理剂量。
核心结论
- 关节突关节存在炎症时,关节内注射皮质类固醇可缓解疼痛并改善功能。
- 骶髂关节注射时,关节内、关节外及联合给药途径均有效。
- 尚无剂量-反应研究,但每个关节突关节10 mg甲基泼尼松龙或曲安奈德、每个骶髂关节40 mg或等效药物是合理剂量。
研究设计与样本
- 共识由美国区域麻醉与疼痛医学学会董事会及其他多家参与学会批准开展。
- 制定方法采用改良德尔菲流程,共识标准为同意率大于75%。
- 证据分级与推荐强度采用美国预防服务工作组分级体系的改良版本。
- 专家按分配主题完成文献综述并起草声明与建议,经讨论、修订和投票后形成共识。
- 所有声明与建议经过四轮讨论并由各参与学会实践指南委员会及董事会批准。
诊断标准与关键数值
- 共识同意纳入的注射技术安全性范围包括体表标志引导、超声引导或影像学辅助注射。
- 共识同意评估在局部麻醉药或生理盐水中加入皮质类固醇是否影响注射有效性。
- 关节突关节每个关节10 mg甲基泼尼松龙或曲安奈德或等效剂量为合理用药建议。
- 骶髂关节每次40 mg甲基泼尼松龙或曲安奈德或等效剂量为合理用药建议。
- 共识同时覆盖不良事件相关内容及重复注射的间隔与标准。
临床应用与阅片要点
- 对疑有关节突关节炎症的患者,可考虑关节内皮质类固醇注射以缓解疼痛和改善功能。
- 骶髂关节注射时关节内、关节外或联合给药均可选择,但共识未给出优先顺序。
- 报告中如实记录注射剂量、给药路径及影像引导方式,避免超剂量重复注射。
- 参照共识给出的剂量范围,不随意提高单次注射剂量,因为有不良事件风险。
局限性
- 原文指出不存在关于皮质类固醇注射的剂量-反应研究。
- 共识依赖现有文献与专家意见,部分建议可能缺乏高水平证据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Corticosteroid injections (CSIs) are widely employed in facet and sacroiliac joint pain. Similar to CSIs at other sites (peripheral nerve blocks, joints, epidural), these injections are associated with potential adverse events. These multisociety consensus recommendations aim to develop evidence-based statements and recommendations on the safe use of CSIs in facet joint and sacroiliac joint injections.
METHODS: Development of the consensus recommendations was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of statements and recommendations was agreed on to include safety of the injection technique (landmark-guided, ultrasound, or radiology-aided injections); effect of the addition of the corticosteroid on effectiveness (vs local anesthetic or saline); and adverse events related to the injection. Experts were assigned topics to perform a comprehensive literature review and draft statements and recommendations, which were refined and voted for consensus (>75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed.
RESULTS: All statements and recommendations were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all statements and recommendations. Injection of corticosteroid into the facet joint in patients with joint inflammation may relieve pain and improves function. Intra-articular, extra-articular (periarticular), and combined administration are effective for sacroiliac joint injections. No dose-response studies exist, but CSIs containing 10 mg of methylprednisolone or triamcinolone per facet joint and 40 mg per sacroiliac joint (SIJ) (or their respective pharmacologic equivalents) are reasonable.
CONCLUSIONS: In this practice recommendation, we provide statements and recommendations on facet and sacroiliac joint CSIs, the optimal doses, and intervals and criteria for repeating the CSIs in patients with facet joint and sacroiliac joint pain.
引用
- Benzon, Doshi, Maus, et al. Multisociety multispecialty consensus recommendations on corticosteroid injections for facet joint and sacroiliac joint pain. Reg Anesth Pain Med. 2026. PMID: 41571428. doi:10.1136/rapm-2025-107347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。